Adocia SA · EURONEXT:ADOC
Adocia SA — Investor Presentation (April 2012)
56 slides from Adocia SA's investor presentation, April 2012

Slide 1: Investor presentation April 2012
Investor presentation April 2012

Slide 2: Disclaimer
Disclaimer This document has been prepared by Adocia (the "Company") solely for use at the presentations organized with investors in connection with the Company's planned initial public offering and the offering to investors in France and outside France (the "Offering"). This document is provided fo

Slide 3: Speakers
Speakers Gérard SOULA Valérie DANAGUEZIAN Olivier SOULA Chairman and CEO CFO R&D Director Ph.D in Organic Chemistry, MBA ISC graduate Ph.D, MBA Founder of Flamel Technologies Former Head of R&D controlling, Aventis Former Director of the Nanotechnologies Pasteur Lyon Department, Flamel Technologies

Slide 4: ADOCIA: Innovative Medicine for Everyone, Everywhere
ADOCIA: “Innovative Medicine for Everyone, Everywhere” 1 Using approved therapeutic proteins … 2 … to license to big pharmas… 3 ... in combination with an innovative proprietary technology: BioChaperone®… 4 … at competitive prices compared to existing treatments… 5 … for developed and emerging count

Slide 5: ADOCIA in brief
ADOCIA in brief Ø A biotechnology company developping innovative formulations with already-approved proteins − Listed on the regulated market of NYSE Euronext in Paris in February 2012 with €27.4 million raised Ø A unique operational technology, BioChaperone® platform, protected by 19 patent applica

Slide 6: ADOCIA IPO: accelerating the company's development
ADOCIA IPO: accelerating the company’s development Ø First IPO on the regulated market of NYSE Euronext in Paris this year – A total of €27,4 million raised – Market cap of approx. €90 million Ø « Top 5 » largest biotechnology companies listed in Paris Ø Additional means to accelerate the company’s

Slide 7: A business model which requires low capital-intensive budgets
A business model which requires low capital-intensive budgets Ø Innovation until the “Proof of Concept” established on human Ø The aim is to license innovative products to major players of pharmaceutical industry − Up-front and milestone payments − Transfer of the full clinical development to partne

Slide 8: Summary
Summary Innovation dedicated to regenerative medicine 1 and chronic disease 2 Product breakthroughs 3 Financials 4 Why investing? Strategy and assets 5 Appendices 8

Slide 9: Innovation dedicated to regenerative medicine and chronic disease
Innovation dedicated 1 to regenerative medicine and chronic disease 9

Slide 10: BioChaperone: a major technological leap
BioChaperone®: a major technological leap BioChaperone®, polysaccharide derivative, mimics the properties of heparin without anti-coagulation activity Ø BioChaperone® forms molecular complexes with therapeutic proteins... Ø ... to improve their efficacy : − Increase in solubility − Protection agains

Slide 11: BioChaperone: an answer to the rise of therapeutic proteins
BioChaperone®: an answer to the rise of therapeutic proteins Ø BioChaperone® polymers have been customised for three classes of proteins Growth factors Hormones Monoclonal antibodies PDGF-BB Insulin Immunoglobulin Regenerative medicine Chronic disease BioChaperone®: a versatile technological platfor

Slide 12: BioChaperone: a well protected technological platform
BioChaperone®: a well protected technological platform Ø An active intellectual property protection strategy Patents on BioChaperone® Patents on BioChaperone® Patents on therapeutic polymers protein complexes applications 9 patent applications 5 patent applications 5 patent applications Ø Internatio

Slide 13: From innovation to pharmaceutical development
From innovation… to pharmaceutical development Ø Development through capital equity with a focus on 2 areas of therapeutic applications − The wound-healing market: diabetic foot ulcers (Phase II completed) • A market estimated at $3 billion(1) − The treatment of diabetes through insulin therapy (1 i

Slide 14: Example: diabetes, a fast-growing market
Example: diabetes, a fast-growing market(1) Growing markets with Explosion of high value emerging added markets ADOCIA has integrated the constraints of two very different markets 14

Slide 15: A strategy adapted to each market
A strategy adapted to each market Our potential partners are already engaged in such a dual strategy Ø Developed countries: a “Value” strategy − Markets driven by prices − Still a strong demand for innovative best-in-class products with an acceptable extra cost Ø Emerging countries: a “Volume” strat

Slide 16: Product breakthroughs
Product breakthroughs 1 Wound healing 2 2 Insulin therapy 3 Formulation of monoclonal antibodies 16

Slide 17: Product breakthroughs: Wound healing
Product breakthroughs 1 Wound healing 2 17

Slide 18: ADOCIA's 1st application in Diabetic Foot Ulcer
The wound healing market: 1 ADOCIA’s 1st application in Diabetic Foot Ulcer (DFU) Ø Diabetic Foot Ulcer − Reaching deep tissues of the foot − Consequence of the destructive effects of diabetes on nerves and arterial circulation within lower members Ø 15% of diabetics worldwide will develop a foot ul

Slide 19: Treatments for diabetic foot ulcers
1 Treatments for diabetic foot ulcers Product Regranex® Gel Fiblast® spray Company Healthpoint biotherapeutics Kaken (Japan) + Olympus Marketed in Japan Status Amputation rate reduced by 30% Phase III in Europe Formulation from PDGF-BB growth factor FGF-2 fibroblast Technology growth factor (approve

Slide 20: BioChaperone PDGF-BB: treating diabetic foot ulcers (1/3)
1 BioChaperone® PDGF-BB: treating diabetic foot ulcers (1/3) Ø Treatment of diabetic foot ulcer with an innovative BioChaperone® polymer associated with the PDGF-BB growth factor (Platelet Derivative Growth Factor) Ø Results of the Phase II clinical trial in India on 195 patients Regranex® vs. BioCh

Slide 21: BioChaperone PDGF-BB: treating diabetic foot ulcer (2/3)
1 BioChaperone® PDGF-BB: treating diabetic foot ulcer (2/3) Week 0 Week 3 Week 6 Ø 3 factors of improvement for ADOCIA’s indication – Cost: dosage of the PDGF-BB divided by 3 compared to that of Regranex® – Compliance: one application every 2 days, compared to once a day with Regranex® – Ease of use

Slide 22: BioChaperone PDGF-BB: treating diabetic foot ulcer (3/3)
1 BioChaperone® PDGF-BB: treating diabetic foot ulcer (3/3) Ø Upcoming clinical trials conducted by ADOCIA − 2012 • Q3: launch of a Phase III in India − 2013 • Q2: launch of a Phase III in Europe • Q2: launch of a Phase III in the US – 2014 • Q1: filing of a NDA for product launch in India 1st marke

Slide 23: BioChaperone PDGF-BB: future developments
1 BioChaperone® PDGF-BB: future developments Ø Venous ulcers − Chronic skin wound that fails to heal spontaneously because of the improper functioning of venous valves − 1% of the population will suffer from at least one venous ulcer during their lives. A 12-month recurrence rate of up to 69%(1) (2)

Slide 24: Product breakthroughs: Insulin therapy
Product breakthroughs 2 Insulin therapy 2 24

Slide 25: Diabetes: a blood sugar disorder
Diabetes: a blood sugar disorder Ø Diabetes: uncapacity of the human body to regulate blood sugar level − Blood sugar level control is normally done by insulin − This control fails for a diabetic, because of: • Lack of insulin production: type 1 diabetes, called insulin-dependent (10% of diabetics)

Slide 26: Insulin therapy: restrictive and complex vital treatment
2 Insulin therapy: restrictive and complex vital treatment Ø Insulin is THE treatment for this condition Ø Current insulin therapies rely on many products and medical devices − Long acting, Fast acting or Premix insulin Global diabetes care market by treatment class − Pen injector, needle or pump −

Slide 27: Insulin therapy: a $17.2 billion market
2 Insulin therapy: a $17.2 billion market(1) Ø A huge market with solid growth over 2011 - 2030 − An increasing number of diabetics: from 366 million to 552 million people (+51%) (2) − Serious or lethal complications: 3.4 million deaths in 2004 around the world are thought to be associated with diab

Slide 28: A dynamic and growing market
2 A dynamic and growing market Ø Human insulin market: $3.1 billion - 17% of the insulin-therapy market(1) Ø Insulin analog market: $14.2 billion(1) Prandial treatment Basal treatment Prandial – Basal treatment (Fast Acting) (Long Acting) (Medium-term and/or Premix) Single injection for both Regulat

Slide 29: BioChaperone Prandial Insulin: strategic positioning
2 BioChaperone® Prandial Insulin: strategic positioning Ø Project n°1 – Human insulin Ø Project n°2 – Insulin analog Ø Humalog® Ø NovoLog® Ø Apidra® Ø Project n°1 – BioChaperone®-Human insulin Ø Project n°2 - BioChaperone®-Analog insulin BioChaperone® could provide a unique property to Prandial Insu

Slide 30: Project n°1 – HinsBet: results of the Phase I clinical trial
2 Project n°1 – HinsBet®: results of the Phase I clinical trial Ø HinsBet® (BioChaperone®-Human insulin) was compared to a fast acting analog (NovoLog) and to human insulin (Actrapid) in a Phase I trial on 12 healthy volunteers (Germany) 14,0 12,0 Insulin ® HinsBet BC 10,0 Regular Insulin ActRapid ®

Slide 31: BioChaperone Prandial Insulin strategic positioning
2 BioChaperone® Prandial Insulin strategic positioning BioChaperone® - Human insulin EFFICACY OF THE TREATMENT Ø Next steps − Q4 2012: launch of a Phase BioChaperone ® IIa clinical trial with an optimised product that Fast acting Human Insulin is more effective on type 1 Fast diabetics acting Analog

Slide 32: Project n°2 – BioChaperone-Insulin analog: preclinical results
2 Project n°2 – BioChaperone®-Insulin analog: preclinical results Ø BioChaperone®-Insulin analog was compared to Insulin Analog in an established preclinical model correlated to humans, pig Time since injection (minutes) BioChaperone®-Insulin analog has a hypoglycaemic action faster and shorter than

Slide 33: First license agreement on ultra-fast-acting insulin analog with a big pharma
First license agreement on «ultra-fast-acting insulin analog» with 2 a big pharma Ø In December 2011, ADOCIA signed a license agreement with a major pharmaceutical group. This agreement deals with the development and the marketing of a fast-acting insulin analog with BioChaperone® technology Ø Terms

Slide 34: BioChaperone Prandial Insulin strategic positioning
2 BioChaperone® Prandial Insulin strategic positioning BioChaperone® - Insulin Analog EASE OF USE AND EFFICACY OF THE TREATMENT BioChaperone ® Ultra-fast acting Analogs Fast acting Analogs PRICE ADOCIA has engaged active collaboration with one of the major insulin pharmaceutical groups 34

Slide 35: Project n°3 – BioChaperone-Insulin Combo: post Premix
2 Project n°3 – BioChaperone®-Insulin Combo: post Premix Ø Premix properties: ensure insulin therapy with one single product Ø Lantus’ market: $4.6 billion NovoMix 30® SINGLE INJECTION AFTER HOMOGENISATION BioChaperone® Lantus Insulin Analog BioChaperone® Combo BC Combo SINGLE INJECTION BioChaperone

Slide 36: BioChaperone-Insulin Combo: preclinical results
2 BioChaperone®-Insulin Combo: preclinical results Ø BioChaperone®-Insulin Combo (BioChaperone® Lantus Apidra) was compared to a double injection of Lantus and Apidra (Lantus Apidra) in an established preclinical model correlated to humans, dog Time since injection (min) long acting + fast acting Bi

Slide 37: BioChaperone-Insulin Combo strategic positioning
2 BioChaperone®-Insulin Combo strategic positioning BioChaperone® -Insulin Combo EASE OF USE AND EFFICACY OF THE TREATMENT Adocia’s Ø Next step BioChaperone® Insulin Combo − Q4 2012: launch of a Phase I clinical trial Premix PRICE Our priority is to partner this project with a big pharma 37

Slide 38: Product breakthroughs: Formulation of monoclonal antibodies
Product breakthroughs 3 Formulation of monoclonal antibodies 2 38

Slide 39: BioChaperone mAbs: innovative monoclonal antibody formulations
3 BioChaperone® mAbs: innovative monoclonal antibody formulations Ø Monoclonal antibodies • Benchmark drugs in the treatment of numerous serious pathologies (chronic inflammatory disease, oncology) • Products with the highest growth in the pharma sector: a market estimated at $32 billion in 2008...

Slide 40: ADOCIA: a solid and diversified product portfolio
ADOCIA: a solid and diversified product portfolio In Vitro Preclinical Clinical Products Phase I Phase II Phase III 1 BioChaperone® PDGF – wound healing Treatment of diabetic foot ulcers Treatment of venous ulcers Treatment of bedsores and burns 2 BioChaperone® Insulin - diabetes Fast Acting BioChap

Slide 41: Financials
ADO C IA ®) Financials innovative medicine for everyone, everywhere

Slide 42: ADOCIA: key figures
ADOCIA: key figures Ø 2011 revenues: €1,6 million (€0,1 million in 2010) – Operating income up 75% – Impact of collaboration agreements, incl. on monoclonal antibodies – First license revenues with the license agreement on a fast-acting insulin analog Ø 2011 operating expenses: €9,7 million (€6,7 mi

Slide 43: ADOCIA: P&L statement
ADOCIA: P&L statement (in thousands €) - IFRS 12/31/2011 12/31/2010 Revenues 1 551 111 Other revenues 2 236 2 036 Total revenues 3 788 2 147 Operating expenses (excl. depreciations and -9 711 -6 683 amortization) Depreciations and amortization -151 -101 EBIT (6 074) (4 637) Other operating revenues

Slide 44: ADOCIA: Condensed balance sheet
ADOCIA: Condensed balance sheet (in thousands €) - IFRS 12/31/2011 12/31/2010 Non-current assets 564 706 Incl. laboratory equipment 378 475 Incl. other tangible assets 179 161 ASSETS Current assets 17 072 14 357 Incl. trade and other receivables 8 039 3 Incl. cash and cash equivalents 5 905 12 024 I

Slide 45: ADOCIA: Cash flow
ADOCIA: Cash flow (in thousands €) - IFRS 12/31/2011 12/31/2010 Net cash provided by or used for operations -6 217 -4 956 Net cash provided by or used for investment activities -155 -137 Net cash provided by or used for financing activities 252 4 418 Changes in net cash -6 119 -674 Cash at January 1

Slide 46: Shareholding structure
Shareholding structure Shareholding structure (Feb. 2012) A solid and diversified shareholding structure 46

Slide 47: Why investing? Strategy and assets
Why investing? 4 Strategy and assets 47

Slide 48: ADOCIA: a virtuous and ambitious growth model
ADOCIA: a virtuous and ambitious growth model Collaborative Products aimed to be BioChaperone® finalised agreements blockbusters and operational and licenses with a global target 1 major license License revenue Potential powerful agreement without waiting for partners products to be Substantial roya

Slide 49: ADOCIA's strategy
ADOCIA’s strategy Ø Become a world leader in the formulation of therapeutic proteins… – Growth factor – Insulin – Monoclonal antibodies Ø … by signing partnerships with big pharmas in the corresponding therapeutic domains An ambitious “innovative leader” strategy 49

Slide 50: ADOCIA: considerable assets
ADOCIA: considerable assets MAJOR TECHNOLOGICAL LEAP Ø BioChaperone®, ADOCIA’s proprietary technological platform VERY SIGNIFICANT Ø Promising clinical results in 2 therapeutic domains worth billions of dollars: the treatment DEVELOPMENT POTENTIAL of chronic wounds and insulin therapy for diabetes L

Slide 51: ADOCIA: substantial short-term newsflow
ADOCIA: substantial short-term newsflow Ø Launch of a phase III study in Q3 2012 in India for the treatment of the diabetic foot ulcer with the PDGF-BB growth factor Ø Launch of a phase I study in Q3 2012 for the treatment of diabetes with fast-acting and slow-acting combo insulins Ø Launch of a sec

Slide 52: Appendices
A D 0 C I Q © Appendices innovative medicine for everyone, everywhere

Slide 53: Notes
Notes 1. SHIRE, annoucement of May 17, 2011 for the acquisition of Advanced Biohealing Page 13 2. Business Insights. The Diabetes Market Outlook to 2016 – May2011 Page 14 1. Wild et al. Diabetes care, volume 27, number 5, 1047-1053 – 2004 1. Reiber GE. Diabetes foot care : financial implications and

Slide 54: BioChaperone: the leading technology for regenerative medicine
BioChaperone® : the leading technology for regenerative medicine Cellular therapy Gene therapy BioChaperone® Ø « Deliberate introduction of genetic material Ø « Transplant of stem cells so as to renew the within somatic human cells so as to repair a Ø « Association of an innovative polymer that func

Slide 55: Strategy de Life Cycle Management on revealed markets
Strategy de Life Cycle Management on revealed markets Development Therapeutic benefit New Shorter time of New intellectual Reduction administration development property of dosage ways New formulation Innovative treatments using = approved proteins Improved efficacy Manufacturing process easily Lower

Slide 56: Stock market: NYSE Euronext Paris – compartment C
• Stock market: NYSE Euronext Paris – compartment C • First listing day: 20 February 2012, at a share price of €15.88 • ISIN code: FR0011184241 • Mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP • Total number of shares: 6,181,776 • Sector: Pharmacy and biotechnology – ICB 4570 • Index: Next Biot
Source: Internet Archive copy of adocia.com
More decks from Adocia SA
Q3 2026 Earnings Presentation19 slides · Nov 2, 2026
Investor Presentation (November 2026)33 slides · November 2026
Investor Presentation (June 2026)43 slides · June 2026
Investor Presentation (March 2026)43 slides · March 2026
Investor Presentation (November 2025)42 slides · November 2025
Shareholder Meeting (June 2025)85 slides · Jun 11, 2025